Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
| العنوان: | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy |
|---|---|
| المؤلفون: | Prashanth Prithviraj, Sagun Parakh, Elizabeth Liniker, M. Khou, Michael Millward, Paul Lorigan, Phillip Parente, Georgina V. Long, Jonathan Cebon, Stefan Diem, Samantha Bowyer, Grant A. McArthur, Benjamin Y. Kong, S. Ramanujam, Victoria Atkinson, Oliver Klein, James Larkin, Matteo S. Carlino, Miles C. Andrews, Alexander Guminski |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Nature Publishing Group, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Phases of clinical research, Ipilimumab, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, ipilimumab, Adverse effect, Pneumonitis, nivolumab, business.industry, Melanoma, immune-mediated adverse event, Retrospective cohort study, medicine.disease, Surgery, 030104 developmental biology, 030220 oncology & carcinogenesis, Clinical Study, pembrolizumab, Nivolumab, business, medicine.drug, metastatic melanoma |
| الوصف: | Background: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. Methods: We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg−1 for a maximum of four doses. Results: Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3–5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3–5 pneumonitis leading to death in one patient. Conclusions: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance. |
| اللغة: | English |
| تدمد: | 1532-1827 0007-0920 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10bbc468c875dc8fdb7ba9d41089227Test http://europepmc.org/articles/PMC4865968Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c10bbc468c875dc8fdb7ba9d41089227 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|